Alnylam Pharmaceuticals
ALNY
784 hedge funds and large institutions have $40.1B invested in Alnylam Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 319 increasing their positions, 280 reducing their positions, and 80 closing their positions.
113% more call options, than puts
Call options by funds: $453M | Put options by funds: $213M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
14% more repeat investments, than reductions
Existing positions increased: 319 | Existing positions reduced: 280
9% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 80
0.64% more ownership
Funds ownership: 99.08% → 99.72% (+0.64%)
1% less funds holding
Funds holding: 791 → 784 (-7)
8% less capital invested
Capital invested by funds: $43.4B → $40.1B (-$3.32B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$249M |
| 2 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$197M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$193M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$145M |
| 5 |
BlackRock
New York
|
+$140M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.1B |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$253M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$96.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$85.5M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$84.2M |
ALNY Hedge Fund Activity: Q2 2026 in Review
784 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2026, worth a combined $40.1B — down 7.7% from $43.4B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new ALNY positions and 80 closed out — a net gain of 7 holders — while 319 added to existing stakes and 280 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $249M. The largest seller was JP Morgan Chase, cutting an estimated $1.1B.
- 784 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2026, down from 791 in Q1 2026.
- Funds reported $40.1B of Alnylam Pharmaceuticals stock for Q2 2026, down 7.7% quarter-over-quarter.
- 87 funds opened new Alnylam Pharmaceuticals positions in Q2 2026 and 80 closed out, a net change of +7 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2026 was Deep Track Capital, an estimated $249M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2026 was JP Morgan Chase, an estimated $1.1B sold.
Based on aggregated 13F filings for Q2 2026.